Upper extremity deep vein thrombosis after suspension of progesterone-only oral treatment

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 5, 2007, Pages 513-517

  Lapecorella, Mario ^a,b   Orecchioni, Assunta ^a   Dell'Orso, Luigi ^a   Mariani, Guglielmo ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b Nuovo Ospedale San Salvatore   (Italy)

Author keywords

G20210A prothrombin; Methylenetetrahydrofolate reductase; Progesterone only oral contraceptives; Thrombophilia; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ETHINYLESTRADIOL; GESTAGEN; HEPARIN; MESTRANOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROTHROMBIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; UTERUS MYOMA; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; PROGESTERONE; PROTHROMBIN; RISK FACTORS; TIME FACTORS; UPPER EXTREMITY; VENOUS THROMBOSIS;

EID: 34250796151     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281a3bed8     Document Type: Article

References (32)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
3. Souto JC, Coll I, Llobet D, del Rio E, Oliver A, Mateo J, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80:366-369.
4. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997; 98:907-909.
5. Fermo I, Vigano' D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123:747-753.
6. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-2698.
7. Boers GH, Fowler B, Smals AG, Trijbels FJ, Leermakers AI, Kleijer WJ, et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69:164-169.
8. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78:327-333.
9. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-1535.
10. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610-1611.
11. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1995; 346:1575-1582.
12. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83-88.
13. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346:1593-1596.
14. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:700-703.
15. Aznar J, Vaya A, Estelles A, Mira Y, Segui R, Villa P, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000; 85:1271-1276.
16. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157:1522-1530.
17. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1-19.
18. Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel- containing oral contraceptives: a review. Am J Obstet Gynecol 1998; 179:S51-S61.
19. Lapecorella M, Marino R, De Pergola G, Scaraggi FA, Speciale V, De Mitrio V. Severe venous thromboembolism in a young man with Klinefelter's syndrome and heterozygosis for both G20210A prothrombin and factor V Leiden mutations. Blood Coagul Fibrinolysis 2003; 14:95-98.
20. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32:269-273.
21. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, et al. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 1991; 82:420-425.
22. Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 86:806-809.
23. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, Ochat N, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2:1594-1600.
24. Lussana F, Zighetti ML, Bucciarelli P, Cugno M, Cattaneo M. Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thromb Res 2003; 112:37-41.
25. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273:9987-9993.
26. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 1997; 126:707-711.
27. Boncoraglio G, Carriero MR, Chiapparini L, Ciceri E, Ciusani E, Erbetta A, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol 2004; 11: 405-409.
28. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88:723-728.
29. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000; 14:1725-1730.
30. Prange-Kiel J, Rune GM, Zwirner M, Wallwiener D, Kiesel L. Regulation of estrogen receptor alpha and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. Exp Clin Endocrinol Diabetes 2001; 109:231-237.
31. Glasier AF, Wang H, Davie JE, Kelly RW, Critchley HO. Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using Norplant: a pilot study. Fertil Steril 2002; 77:366-372.
32. Arkel YS, Paidas MJ, Ku DH. The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagul Fibrinolysis 2002; 13:199-205.